The share price fell 11 percent. Moderna has announced that vaccine sales this year will range between $15 billion and $18 billion (about $13 billion to $15.6 billion). The company earlier said it had signed deals worth $20 billion (17.3 billion euros) in expected vaccine sales by 2021.
Moderna also lowered its forecast for vaccine production this year to 700 million to 800 million doses. According to Moderna, some deliveries could be delayed until 2022. The company is talking about a “temporary effect” and is trying to expand the capacity to fill and finish vaccine vials.
In the third quarter, Moderna’s performance was below analyst expectations. The company recorded sales of 5 billion dollars (4.3 billion euros). Moderna has announced that it has included $17 billion (€14.7 billion) in vaccine orders for 2022.
Moderna rivals Pfizer and BioNTech are struggling to get their booster shots for next year.
Earlier this week, Pfizer raised its forecast for 2021 vaccine sales.
See also: The Moderna vaccine was found to be 94.5 percent effective
“Total coffee specialist. Hardcore reader. Incurable music scholar. Web guru. Freelance troublemaker. Problem solver. Travel trailblazer.”
More Stories
Bitcoin transaction fees crash hard after bizarre halving spike
Ethereum (ETH) is heading towards the $5,000 level, despite the recent decline
Ripple CEO reveals strategy for the next three years